Literature DB >> 27565766

Spectroscopic investigation of the interaction between G-quadruplex of KRAS promoter sequence and three isoquinoline alkaloids.

Li-Na Wen1, Meng-Xia Xie2.   

Abstract

KRAS promoter can form G-quadruplex structure and regulate gene transcription. The drugs which can bind with G-quadruplex of KRAS promoter may be potential remedy for treatment of cancers associated with KRAS mutation. The interaction mechanism between the G-quadruplex of KRAS promoter and three isoquinoline alkaloids (jatrorrhizine, berberine and sanguinarine) has been investigated by UV-visible, fluorescence and circular dichroism spectroscopic methods. The results showed that the three alkaloids can form complexes with G-quadruplex KRAS promoter with the molecular ratio of 1:1, and the binding constants were (0.90±0.16)×106Lmol-1, (0.93±0.21)×106Lmol-1 and (1.16±0.45)×106Lmol-1 for jatrorrhizine, berberine and sanguinarine. The absorption spectra, KI quenching and fluorescence anisotropy and polarization studies suggested jatrorrhizine and berberine interacted with G-quadruplex by not only end-stacking binding mode but also grooves or loops binding mode, while sanguinarine by end-stacking binding mode. Sanguinarine was more beneficial to maintain the stability and parallel conformation of KRAS promoter G-quadruplex. MTT assay was performed to evaluate antiproliferation effects of the three isoquinoline alkaloids on SW620 cells, and the antiproliferation effects of the three alkaloids were sanguinarine > berberine > jatrorrhizine. All the three alkaloids can bind with KRAS promoter G-quadruplex, and sanguinarine had the better binding property and antiproliferation effects on SW620 cells. The results obtained are meaningful to explore potential reagents targeting the parallel G-quadruplex structure of KRAS promoter for gene theraphy of colorectal carcinomas.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Binding mode; Isoquinoline alkaloids; KRAS promoter quadruplex; Spectroscopy

Mesh:

Substances:

Year:  2016        PMID: 27565766     DOI: 10.1016/j.saa.2016.08.013

Source DB:  PubMed          Journal:  Spectrochim Acta A Mol Biomol Spectrosc        ISSN: 1386-1425            Impact factor:   4.098


  6 in total

1.  c-MYC and HIF1α promoter G-quadruplexes dependent metabolic regulation mechanism of berberine in colon cancer.

Authors:  Lina Wen; Zongqiang Han; Jianhui Li; Yanlin Du
Journal:  J Gastrointest Oncol       Date:  2022-06

2.  Design and Synthesis of Tetrahydroisoquinoline Derivatives as Anti-Angiogenesis and Anti-Cancer Agents.

Authors:  Madhavi Gangapuram; Suresh Eyunni; Wang Zhang; Kinfe K Redda
Journal:  Anticancer Agents Med Chem       Date:  2021       Impact factor: 2.505

Review 3.  Jatrorrhizine: A Review of Sources, Pharmacology, Pharmacokinetics and Toxicity.

Authors:  Furong Zhong; Yang Chen; Jia Chen; Hailang Liao; Yirou Li; Yuntong Ma
Journal:  Front Pharmacol       Date:  2022-01-13       Impact factor: 5.810

4.  Effects of G-Quadruplex-Binding Plant Secondary Metabolites on c-MYC Expression.

Authors:  Roman G Zenkov; Kirill I Kirsanov; Anna M Ogloblina; Olga A Vlasova; Denis S Naberezhnov; Natalia Y Karpechenko; Timur I Fetisov; Ekaterina A Lesovaya; Gennady A Belitsky; Nina G Dolinnaya; Marianna G Yakubovskaya
Journal:  Int J Mol Sci       Date:  2022-08-16       Impact factor: 6.208

5.  Structural insight into the bulge-containing KRAS oncogene promoter G-quadruplex bound to berberine and coptisine.

Authors:  Kai-Bo Wang; Yushuang Liu; Jinzhu Li; Chengmei Xiao; Yingying Wang; Wei Gu; Yipu Li; Yuan-Zheng Xia; Tingdong Yan; Ming-Hua Yang; Ling-Yi Kong
Journal:  Nat Commun       Date:  2022-10-12       Impact factor: 17.694

6.  Characterization of clinically used oral antiseptics as quadruplex-binding ligands.

Authors:  David R Calabrese; Katherine Zlotkowski; Stephanie Alden; William M Hewitt; Colleen M Connelly; Robert M Wilson; Snehal Gaikwad; Lu Chen; Rajarshi Guha; Craig J Thomas; Beverly A Mock; John S Schneekloth
Journal:  Nucleic Acids Res       Date:  2018-04-06       Impact factor: 16.971

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.